Cardiac Arrhythmia Service, MGH Heart Center, Massachusetts General Hospital, Boston, MA, United States of America.
PLoS One. 2021 Nov 3;16(11):e0259123. doi: 10.1371/journal.pone.0259123. eCollection 2021.
Lyme carditis, defined as direct infection of cardiac tissue by Borrelia bacteria, affects up to 10% of patients with Lyme disease. The most frequently reported clinical manifestation of Lyme carditis is cardiac conduction system disease. The goal of this study was to identify the incidence and predictors of permanent pacemaker implantation in patients hospitalized with Lyme disease.
A retrospective cohort analysis of the Nationwide Inpatient sample was performed to identify patients hospitalized with Lyme disease in the US between 2003 and 2014. Patients with Lyme carditis were defined as those hospitalized with Lyme disease who also had cardiac conduction disease, acute myocarditis, or acute pericarditis. Patients who already had pacemaker implants at the time of hospitalization (N = 310) were excluded from the Lyme carditis subgroup. The primary study outcome was permanent pacemaker implantation. Secondary outcomes included temporary cardiac pacing, permanent pacemaker implant, and in-hospital mortality.
Of the 96,140 patients hospitalized with Lyme disease during the study period, 10,465 (11%) presented with Lyme carditis. Cardiac conduction system disease was present in 9,729 (93%) of patients with Lyme carditis. Permanent pacemaker implantation was performed in 1,033 patients (1% of all Lyme hospitalizations and 11% of patients with Lyme carditis-associated conduction system disease). Predictors of permanent pacemaker implantation included older age (OR: 1.06 per 1 year; 95% CI:1.05-1.07; P<0.001), complete heart block (OR: 21.5; 95% CI: 12.9-35.7; P<0.001), and sinoatrial node dysfunction (OR: 16.8; 95% CI: 8.7-32.6; P<0.001). In-hospital mortality rate was higher in patients with Lyme carditis (1.5%) than in patients without Lyme carditis (0.5%).
Approximately 11% of patients hospitalized with Lyme disease present with carditis, primarily in the form of cardiac conduction system disease. In this 12-year study, 1% of all hospitalized patients and 11% of those with Lyme-associated cardiac conduction system disease underwent permanent pacemaker implantation.
莱姆心炎,定义为伯氏疏螺旋体直接感染心脏组织,影响多达 10%的莱姆病患者。莱姆心炎最常报告的临床表现是心脏传导系统疾病。本研究的目的是确定住院莱姆病患者中永久性心脏起搏器植入的发生率和预测因素。
对全国住院患者样本进行回顾性队列分析,以确定美国 2003 年至 2014 年期间住院的莱姆病患者。莱姆心炎患者定义为因莱姆病住院且同时患有心脏传导疾病、急性心肌炎或急性心包炎的患者。在住院时已经植入起搏器的患者(N=310)被排除在莱姆心炎亚组之外。主要研究结果为永久性心脏起搏器植入。次要结果包括临时心脏起搏、永久性心脏起搏器植入和住院死亡率。
在研究期间,96140 例因莱姆病住院的患者中,有 10465 例(11%)患有莱姆心炎。93%(9729/10465)的莱姆心炎患者存在心脏传导系统疾病。1033 例(1%的所有莱姆病住院患者和 11%的莱姆病相关传导系统疾病患者)接受了永久性心脏起搏器植入。永久性心脏起搏器植入的预测因素包括年龄较大(每增加 1 年的 OR:1.06;95%CI:1.05-1.07;P<0.001)、完全性心脏传导阻滞(OR:21.5;95%CI:12.9-35.7;P<0.001)和窦房结功能障碍(OR:16.8;95%CI:8.7-32.6;P<0.001)。莱姆心炎患者的住院死亡率(1.5%)高于无莱姆心炎患者(0.5%)。
约 11%的莱姆病住院患者患有心肌炎,主要表现为心脏传导系统疾病。在这项为期 12 年的研究中,所有住院患者的 1%和与莱姆病相关的心脏传导系统疾病患者的 11%接受了永久性心脏起搏器植入。